Giuseppe Saglio: Influence Statistics

Giuseppe Saglio

Giuseppe Saglio

Divisione Universitaria di Ematologia e Terapie Cellulari, A.O. Ordine Mauriziano, Turin. | Department of Clinical and Biological Sciences, University of Torino, Torino, Italy ...

Giuseppe Saglio: Expert Impact

Concepts for which Giuseppe Saglio has direct influence: Sokal score , 12 months , Generic imatinib , Chronic myeloid leukemia , Chronic myeloid , Myeloid leukemia , Cml patients .

Giuseppe Saglio: KOL impact

Concepts related to the work of other authors for which for which Giuseppe Saglio has influence: Chronic myeloid leukemia , Imatinib mesylate , Bcr abl , Cml patients , Kinase inhibitors , Philadelphia chromosome .

KOL Resume for Giuseppe Saglio

Year
2022

Divisione Universitaria di Ematologia e Terapie Cellulari, A.O. Ordine Mauriziano, Turin.

Department of Clinical and Biological Sciences, University of Torino, Torino, Italy

2021

A.S.O. Ordine Mauriziano, Struttura Complessa a Direzione Universitaria‐Ematologia e Terapie Cellulari‐, P.O. Umberto I, Torino, Italy

2020

Department of Clinical and Biological Sciences, University of Turin, 10043 Orbassano, Italy;, (G.R.C.);, (P.B.);, (G.S.);, (C.F.)

2019

Department of Clinical and Biological Sciences, University of Turin, Orbassano (TO), Italy;

Università Torino, Turin, Italy.

2018

Department of Clinical and Biological Sciences, University of Turin, Orbassano, Turin, Italy

2015

Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy

2011

Dept. of Clinical and Biological Sciences, University of Turin, Orbassano, Italy,

2010

Laboratorio di Medicina e Oncologia, Molecolare, Universita degli Studi di Torino, Orbassano, Italy,

Division of Hematology, University of Turin, Orbassano, Italy

2009

Department of Clinical and Biological Sciences, University of Orbassano, Turin, Italy,

2005

Hematology, Piedmont MDS Registry, Alessandria, Italy

2004

Hematology and Internal Med., Univ. of Turin, Italy

Prominent publications by Giuseppe Saglio

KOL-Index: 12003 . It is judged safe to discontinue treatment with tyrosine kinase inhibitors (TKI) for chronic myeloid leukemia (CML) in experimental trials on treatment-free remission (TFR). We collected a total of 293 Italian patients with chronic phase CML who discontinued TKI in deep molecular response. Seventy-two percent of patients were on treatment with imatinib, and 28% with second generation TKI ...
Known for Tyrosine Kinase Inhibitors | Chronic Myeloid | Deep Molecular Response | Treatment Tki
KOL-Index: 10016 . BACKGROUND: Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a selective inhibitor of this kinase. METHODS: A total of 532 patients with late--chronic-phase CML in whom previous therapy with interferon alfa had failed were treated with 400 mg of oral imatinib daily. Patients were ...
Known for Cytogenetic Responses | Imatinib Mesylate | Myelogenous Leukemia | Toxic Effects
KOL-Index: 8900 . Several papers authored by international experts have proposed recommendations on the management of BCR-ABL1+ chronic myeloid leukemia (CML). Following these recommendations, survival of CML patients has become very close to normal. The next, ambitious, step is to bring as many patients as possible into a condition of treatment-free remission (TFR). The Gruppo Italiano Malattie ...
Known for Chronic Myeloid Leukemia | Free Remission | Tki Tfr | 12 Months
KOL-Index: 6261 . Despite the advent of tyrosine kinase inhibitors, a proportion of chronic myeloid leukemia patients in chronic phase fail to respond to imatinib or to second-generation inhibitors and progress to blast crisis. Until now, improvements in the understanding of the molecular mechanisms responsible for chronic myeloid leukemia transformation from chronic phase to the aggressive blast crisis ...
Known for Chronic Myeloid | Bcrabl Positive Leukemia | Blast Crisis | Tyrosine Kinase Inhibitors
KOL-Index: 2938 . Limited information is available on the impact of the COVID-19 pandemic on the management of chronic myeloid leukaemia (CML). The Campus CML network collected retrospective information on 8 665 CML patients followed at 46 centres throughout Italy during the pandemic between February 2020 and January 2021. Within this cohort, we recorded 217 SARS-CoV-2-positive patients (2·5%). Most ...
Known for Cml Patients | Sarscov2 Infection | Chronic Myeloid | Leukemia Myelogenous
KOL-Index: 1787 . An observational prospective study was conducted by the CML Italian network to analyze the role of baseline patient characteristics and first line treatments on overall survival and CML-related mortality in 1206 newly diagnosed CML patients, 608 treated with imatinib (IMA) and 598 with 2nd generation tyrosine kinase inhibitors (2GTKI). IMA-treated patients were much older (median age 69 ...
Known for Myeloid Leukemia | Cml Patients | Elts Score | Patient Characteristics

Key People For Sokal Score

Top KOLs in the world
#1
Michele Baccarani
chronic myeloid leukemia speakers bureau consultancy honoraria
#2
Hagop Meguerditch Kantarjian
consultancy funding board directors advisory committees
#3
Andreas Hochhaus
honoraria funding chronic myeloid leukemia novartis consultancy
#4
François Guilhot
chronic myeloid leukemia speakers bureau honoraria funding
#5
Francisco Cervantes
speakers bureau chronic myeloid leukemia primary myelofibrosis
#6
Rüdiger Hehlmann
chronic myeloid leukemia honoraria funding cml patients

Divisione Universitaria di Ematologia e Terapie Cellulari, A.O. Ordine Mauriziano, Turin. | Department of Clinical and Biological Sciences, University of Torino, Torino, Italy | A.S.O. Ordine Mauriziano, Struttura Complessa a Direzione Universitaria‐